di , 07/12/2022

The company was recognized for its achievements in the Computer-Aided Imaging category

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Iterative Health, a pioneer in precision-medicine technologies for gastroenterology, today announced that it has been named one of CB Insights’ top 150 companies in Digital Health for 2022, the second year in a row in which it has made this list. The Digital Health 150 is CB Insights’ annual ranking of the 150 most promising digital health startups in the world. Iterative Health was recognized in the Computer-Aided Imaging category.

“For the second year in a row, we are honored to be recognized alongside such impactful organizations, working towards a common goal of improving healthcare outcomes,” said Jonathan Ng, founder and CEO of Iterative Health. “2022 has been a transformative year for Iterative Health, from FDA clearance of our first product, to growing the team by over fivefold and adding some incredible talent to our team. This award demonstrates the tremendous effort our team puts in everyday to develop technology that will benefit patients everywhere.”

Iterative Health was selected from a pool of over 13,000 private companies and was chosen based on its R&D activity, market potential, business relationships, investor profile, competitive landscape, team strength, and tech novelty.

The company is a pioneer in the application of advanced artificial intelligence (AI) tools in gastroenterology. To date, it has raised $195M in funding and is rapidly growing in pursuit of its mission to use computer vision-based technology to reduce disparities in healthcare.

“From reimagining clinical care, to leveraging tech like AR/VR to improve surgical training, this year’s Digital Health 150 winners are transforming the future of healthcare with digital technology,” said Brian Lee, SVP of CB Insights’ Intelligence Unit. “This increasingly global cohort is not only driving better patient outcomes but making healthcare more accessible. We are excited to follow the meaningful impact and continued success of this year’s winners.”

To learn more about Iterative Health’s plan to redefine the current approach to gastrointestinal care with AI, please visit iterative.health.

About CB Insights

CB Insights builds software that enables the world’s best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.

About Iterative Health

Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD) and improving the accuracy of colorectal cancer screenings. We use advanced machine learning and computer vision to interpret endoscopic images along with other types of data, helping clinicians to better assess patients with potential GI problems. This gives practitioners enhanced capabilities in the detection, annotation, disease scoring and treatment of GI-related diseases. The company is based in Cambridge, Massachusetts with offices across the United States.


Ariel Rapoport, Marketing Manager

Iterative Health